Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes
OwnerLothar Faerber, Wolfgang Mueller +1inventors
InventorsLothar Faerber, Wolfgang Mueller, Thomas Stratz
Life of this patent
Estimating the term…
Abstract
The present invention relates to a new use for compounds having 5-HT3 (serotonin M) receptor antagonist activity, especially tropisetron, for the manufacture of a pharmaceutical composition for the systemic treatment of an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present.
Claims10
The use of a 5-HT3 receptor antagonist or of a pharmaceutically acceptable salt of such an antagonist for the manufacture of a pharmaceutical composition for the systemic treatment of an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present.
A method of systemically treating an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present in a subject in need thereof, which method comprises administering to said subject an effective amount of a 5-HT3 receptor antagonist.
A method of providing replacement therapy for anti-inflammatory glucocorticosteroid therapy in a subject receiving such glucocorticosteroid therapy, said subject suffering from an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present, which method comprises systemically administering to said subject an effective amount of a 5-HT3-receptor antagonist.
A method of systemically treating an inflammatory rheumatic or rheumatoid disease other than crystal induced arthritis and other than living pathogen induced inflammatory diseases as long as the living pathogen is still present in a subject in need thereof, which method comprises administering to said subject an effective amount of a 5-HT3 receptor antagonist together with an anti-inflammatory glucocorticosteroid.
The use of a 5-HT3 receptor antagonist for the manufacture of a pharmaceutical composition for systemic use:
- a) in the treatment of any inflammatory process, condition, event or disease as hereinbefore described;
- b) as replacement therapy for anti-inflammatory glucocorticosteroid therapy in the treatment of any inflammatory process, condition, event or disease as hereinbefore described;
- or
- c) for co-administration together with an anti-inflammatory glucocorticosteroid in the treatment of any inflammatory process, condition, event or disease as hereinbefore described.
Dependencies are inferred from the claim text.